Related Experiment Video
Updated: Jan 13, 2026
07:14
Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
Published on: May 23, 2025
1.5K
[Meningeal carcinomatosis].
J J Baiges-Octavio1, M Huerta-Villanueva
1Hospital Verge de la Cinta, Tortosa, Tarragona, España.
Revista De Neurologia
|February 24, 2001
Summary
Meningeal carcinomatosis, a complication of advanced cancers, requires high clinical suspicion for diagnosis. Early detection of neurological signs and malignant cells in cerebrospinal fluid is crucial for timely treatment.
Area of Science:
- Oncology
- Neurology
- Pathology
Context:
- Meningeal carcinomatosis (MC) is a severe complication of solid tumors, notably breast, lung, and melanoma adenocarcinomas.
- MC typically presents in advanced cancer stages, often with a poor prognosis and short survival rates.
- Increased incidence of MC is linked to improved survival in systemic cancer patients.
Purpose:
- This review synthesizes current knowledge on the etiopathogenesis, clinical presentation, diagnosis, and treatment of meningeal carcinomatosis.
- Emphasis is placed on otoneurophthalmological manifestations and diagnostic neuroimaging techniques.
- The objective is to provide a comprehensive overview for clinicians managing this challenging condition.
Summary:
- MC involves various nervous system levels, presenting with diverse neurological symptoms, including sudden vision or hearing loss.
- Diagnostic confirmation relies on neuroimaging (CT, MRI, CSF flow studies) and cytological analysis of cerebrospinal fluid (CSF).
- Treatment strategies are individualized, combining intrathecal chemotherapy, radiotherapy, and potentially systemic chemotherapy.
Impact:
- Early diagnosis of MC is critical due to its ominous prognosis.
- Prompt identification of neurological signs and CSF cytology aids in confirming the diagnosis.
- Tailored treatment approaches, including chemotherapy and radiotherapy, can improve outcomes for patients with meningeal carcinomatosis.
